ENDO: More Than Half of Adults With T2DM Who Discontinue GLP-1 Receptor Agonists Reinitiate Treatment

WEDNESDAY, June 17, 2026 (HealthDay News) -- More than half of adults with type 2 diabetes mellitus (T2DM) who discontinue glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reinitiate within one year, according to a study presented at ENDO 2026, the annual meeting of the Endocrine Society, held from June 13 to 16 in Chicago.Sainikhil Sontha, from the Boston University Chobanian and Avedisian School of Medicine, and colleagues conducted a retrospective cohort study using claims data from January 2019 to June 2025 for adults aged 18 to 64 years with body mass index ≥25 kg/m2 and T2DM who initiated liraglutide, semaglutide, or tirzepatide to examine patterns of discontinuation and reinitiation.The researchers found that among 60,222 patients with T2DM in the discontinuation cohort, the rates of discontinuation at one and two years were 41.5 and 58.0 percent, respectively. Compared with liraglutide, tirzepatide and semaglutide were associated with substantially lower risks of discontinuation (hazard ratios [HRs], 0.59 and 0.72, respectively). An increased risk for discontinuation was seen for Medicaid and Medicare coverage (HRs, 1.18 and 1.17, respectively) and for Black or African American race/ethnicity (HR, 1.17); risk was lower for endocrinologist-initiated prescription and ≥5 percent weight loss (HRs, 0.90 and 0.91, respectively). Of the 14,196 patients with T2DM who discontinued, 53.6 and 65.9 percent reinitiated within one and two years, respectively. Higher hazards of reinitiation were seen in Black or African American patients, those with ≥5 percent weight gain, users of tirzepatide, and users of semaglutide (HRs, 1.25, 1.10, 1.12, and 1.13, respectively). Lower reinitiation was predicted by Medicaid and Medicare coverage (HRs, 0.86 and 0.93, respectively). The most common reason for discontinuation was gastrointestinal adverse events."For many patients, these medications aren't being abandoned permanently; use is more start-and-stop than most people assumed," Sontha said in a statement.Press ReleaseMore Information.Sign up for our weekly HealthDay newsletter

ENDO: More Than Half of Adults With T2DM Who Discontinue GLP-1 Receptor Agonists Reinitiate Treatment

Related Stories

ENDO: Significant Decrease in Physical Activity Seen After GLP-1 Receptor Agonist Initiation

ENDO: GLP-1 Receptor Agonists Tied to Higher Hypotension Risk in Patients on BP Meds

ENDO: Few Men Receiving Testosterone Undergo Guideline-Concordant Diagnostic Testing

Half Of U.S. Parents Track Their Adult Children’s Location